# Nuvalent (stock symbol: NUVL) Logo in transparent PNG and SVG formats

## Nuvalent Logo large

### Nuvalent Logo large Download PNG (35.31 KB)

![Nuvalent Logo large Download PNG (35.31 KB)](/img/orig/NUVL_BIG-311c2cb3.png)

### Nuvalent Logo large Download SVG (3.27 KB)

![Nuvalent Logo large Download SVG (3.27 KB)](/img/orig/NUVL_BIG-3ea6c10f.svg)

## Nuvalent Logo icon format

### Nuvalent Logo icon format Download PNG (69.52 KB)

![Nuvalent Logo icon format Download PNG (69.52 KB)](/img/orig/NUVL-db8d5ece.png)

### Nuvalent Logo icon format Download SVG (644 Bytes)

![Nuvalent Logo icon format Download SVG (644 Bytes)](/img/orig/NUVL-9b179f5f.svg)

## Nuvalent Logo large for dark backgrounds

### Nuvalent Logo large for dark backgrounds Download PNG (34.39 KB)

![Nuvalent Logo large for dark backgrounds Download PNG (34.39 KB)](/img/orig/NUVL_BIG.D-2328822e.png)

### Nuvalent Logo large for dark backgrounds Download SVG (2.69 KB)

![Nuvalent Logo large for dark backgrounds Download SVG (2.69 KB)](/img/orig/NUVL_BIG.D-e5e3eaf8.svg)

## Nuvalent Logo icon format for dark backgrounds

### Nuvalent Logo icon format for dark backgrounds Download PNG (70.11 KB)

![Nuvalent Logo icon format for dark backgrounds Download PNG (70.11 KB)](/img/orig/NUVL.D-c2905cec.png)

### Nuvalent Logo icon format for dark backgrounds Download SVG (644 Bytes)

![Nuvalent Logo icon format for dark backgrounds Download SVG (644 Bytes)](/img/orig/NUVL.D-42c3a9f1.svg)

## About Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

1. Website domain: nuvalent.com
2. Employees: 57
3. Marketcap: $2.00 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
